Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Summary

The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.

Timeline

Start

2015-11-04

Primary completion

2017-08-17

Completion

2017-08-17

Outcome

Met primary endpoint

registry analysis (superiority test); LHW090 100 mg vs Placebo; p = 0.002; Mean Difference (Net) -8.555 (95% CI -14.388 to -2.722) NCT02515331 ↗

registry analysis (superiority test); LHW090 200 mg vs Placebo; p <0.001; Mean Difference (Net) -14.727 (95% CI -20.852 to -8.602) NCT02515331 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LHW090	Unknown	100 mg	Oral
Subject	LHW090	Unknown	200 mg	Oral

Indications